articleThe LancetFeb 12, 2016GREEN OA

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

PSPatrick SchöffskiSPSant P. ChawlaRGRobert G. MakiAIAntoîne ItalianoHGHans Gelderblom

KU Leuven · Sarcoma Oncology Center · +20 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

761
total citations
FWCI
78.91
Percentile
100%
References
30
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Eribulin
  • Medicine
  • Dacarbazine
  • Soft tissue sarcoma
  • Liposarcoma
  • Internal medicine
  • Clinical endpoint
  • Tolerability
No related works found for this paper.

Funding